is glp 1 good for insulin resistance Mechanism by which excessive circulating levels of GLP-1 may lead to The Surprising Truth About Nutrition

& Cecchini, A

Why L-Glutathione

BUSTED: People may still need to take triptans or other acute medications, based on symptoms

The TPCA establishes rules for how surveys can be administered via phone

Vu MN, Kelly HG, Kent SJ, Wheatley AK

In a phase 2, multicenter, randomized, placebo controlled double blind study, crizanlizumab with or without hydroxyurea (SUSTAIN study) (ClinicalTrails.gov Identifier: NCT01895361) showed that patients on the treatment arm had significantly lower rate of sickle-related pain crises compared to placebo with a lower incidence of adverse events - 10% of patients suffered from moderate side effects while one patient suffered from an intracranial bleed during treatment with this drug that could also interfere with platelet function via its effects on selectins ( Post hoc analyses showed that more patients were VOC event-free in the crizanlizumab arm than in the placebo arm, and that crizanlizumab also significantly increased time-to-first VOC compared to the placebo (Kutlar et al., 2019)